Jiangsu Vcare Included in "2024 Jiangsu Provincial Sci-Tech Enterprise Listing Cultivation Program"
Published Time:
2024-10-28 17:53
Source:
Recently, the Jiangsu Provincial Department of Science and Technology announced the "2024 Proposed Enterprises for Provincial Sci-Tech Enterprise Listing Cultivation Program," withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) successfully included.
This program targets high-tech enterprises, selecting high-growth sci-tech enterprises with sound governance, focused core businesses, strong competitiveness, and development potential. Its goal is to facilitate financing channels for high-tech enterprises and connect them with multi-level capital markets. Jiangsu Vcare's inclusion reflects the Provincial Department of Science and Technology's recognition of its comprehensive development potential and technological innovation. The company will continue focusing on its core responsibilities to accelerate its listing process.
As aNational "Little Giant" Enterprise, Jiangsu Vcare has specialized in innovative drugs and advanced therapies for 14 years, operating under a group management model with a high-quality R&D and production team of nearly 1,000. It currently has5 clinical-stage Class I innovative drug projectsand over10 preclinical projects, featuring a pipeline centered on the anti-platelet drug Vicagrel,covering therapeutic areas including cardiovascular, oncology, and autoimmune diseases.
With support from this program, Jiangsu Vcare will advance steadily toward listing, enhancing its core competitiveness to contribute to Jiangsu's and China’s technological and economic progress.
Related News
17
2024
/
10
Jiangsu Vcare's New-generation TRK Inhibitor VC004 Obtains IND Approval from the US FDA
On October 16, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (referred to as "Jiangsu Vcare")'s independently developed new-generation anti-resistant TRK inhibitor VC004 achieved a significant milestone progress, and the project officially obtained the Investigational New Drug (IND) permission from the US Food and Drug Administration (FDA). This fully demonstrates Jiangsu Vcare's excellent drug research and development capabilities and is a successful practice of the company's strategies based on original innovation, high-quality standards, and a global layout.
View Details
24
2024
/
09
Jiangsu Vcare’s Next-Generation TRK Inhibitor VC004 IND Application was accepted by the US FDA
At the end of September 2024, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that the US FDA has officially accepted the Investigational New Drug (IND) application of its independently developed new-generation anti-resistant TRK inhibitor VC004. This milestone paves the way for the global commercialization strategy.
View Details
09
2024
/
09
Recently, the Ministry of Industry and Information Technology (MIIT) announced the sixth batch of National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises, andJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was successfully selected. Thisnational-levelhonor fully demonstrates that under its "dual-core business model," Jiangsu Vcare's scientific research capabilities, independent innovation capacity, market leadership, and future development potential have received official high recognition.
View Details
16
2024
/
08
Jiangsu Vcare Announces Successfully Unblinding of VC005 Topical Gel Clinical Phase I Data
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful unblinding of Phase I clinical data for its self-developed VC005 gel, a second-generation selective JAK1 inhibitor, in the topical treatment of mild-to-moderate atopic dermatitis (AD). The results demonstrated exceptional safety and significant efficacy.
View Details
14
2024
/
08
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced positive topline data from its Phase II clinical trial of VC005 tablets, a second-generation selective JAK1 inhibitor, for the oral treatment of moderate-to-severe atopic dermatitis (AD).
View Details
19
2024
/
07
Announcement on Company Name Change by Jiangsu Vcare Pharmatech Co., Ltd.
July 12, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (hereinafter referred to as "the Company") has completed the industrial and commercial registration for its name change and obtained the renewed Business License issued by the Administrative Approval Bureau of Nanjing Jiangbei New Area.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn